Magic mushroom compound shows promise for Tough-to-Treat depression and BPD
NCT ID NCT05399498
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This small Phase 2 trial tested a single 25mg dose of psilocybin in 9 adults with both major depressive disorder and borderline personality disorder. Researchers measured changes in depression and BPD symptoms over time. The goal was to see if psilocybin is safe and could help ease symptoms in this complex group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
psilocybin (a psychedelic compound)
What this could lead to
If it works, this could point toward a new treatment option for people with both depression and borderline personality disorder.
What could go wrong
This is a very small, early-stage trial with only 9 participants, so results may not apply to everyone. Psychedelic therapy can cause intense emotional experiences and is not without risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Chicago
Chicago, Illinois, 60637, United States